Two-Year Data Show Patients Receiving Simponi (golimumab ... - PharmaLive.com (press release)

Two-Year Data Show Patients Receiving Simponi (golimumab ... PharmaLive.com (press release), PA Improvements in the Assessment in Ankylosing Spondylitis criteria (ASAS 20) were maintained through two years in each of the study arms: "In the GO-RAISE trial, treatment with golimumab provided sustained symptom relief to patients living with the ... New Analysis Shows Efficacy of Simponi (golimumab) in Anti-TNF ... PharmaLive.com (press release) all 3 news articles

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab ... - FOXBusiness

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab ... FOXBusiness Improvements in the Assessment in Ankylosing Spondylitis criteria (ASAS 20) were maintained through two years in each of the study arms: "In the GO-RAISE trial, treatment with golimumab provided sustained symptom relief to patients living with the ...

WFWS "After Market Most Active by Volume -NYSE" - Exxon - TransWorldNews (press release)

WFWS "After Market Most Active by Volume -NYSE" - Exxon TransWorldNews (press release), GA Its products include REMICADE, a biologic to treat Crohn's disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and used to treat rheumatoid arthritis; TOPAMAX, for adjunctive and monotherapy use in epilepsy, ...